#USA #San Diego #Sobi #ASH 2024 #Haematology

Sobi's Haematology Innovations to Shine at ASH 2024

Sobi, a leader in biopharmaceuticals, is set to showcase exciting new data at the 66th Annual Meeting of the American Society of Hematology (ASH), taking place from December 7 to 10, 2024, in sunny San Diego, California. The conference will highlight significant advancements in the treatment of various haematological disorders, including haemophilia A, haemophagocytic lymphohistiocytosis (HLH), myelofibrosis, paroxysmal nocturnal hemoglobinuria (PNH), and immune thrombocytopenia (ITP).

Dr. Lydia Abad-Franch, Head of Research at Sobi, stated, "Haemophilia A has a long-lasting effect on joint health and overall quality of life. Our presentations at ASH 2024 will share crucial findings regarding long-term outcomes associated with ALTUVOCT® prophylaxis. We will also delve into other profound rare diseases, demonstrating our commitment to pushing forward innovative treatments in this field. We eagerly anticipate sharing our insights in San Diego."

Highlights from Sobi at ASH 2024

Sobi's presentations will cover critical aspects of haematology, with key sessions focusing on:

1. Haemophilia A

• - ALTUVOCT® (efanesoctocog alfa): This high-sustained FVIII replacement therapy stands out for its unique ability to provide near-normal factor activity levels through weekly dosage. New data will explore its impact on joint health and quality of life, including:

- Association Between Hemophilia Joint Health Score and Quality of Life
- Date: December 9, 2024, 11:30 AM
- Clinical Outcomes Over Three Years of Treatment
- Date: December 9, 2024, 11:00 AM
- Real-World Experience with Efanesoctocog Alfa
- Date: December 7, 2024, 1:00 PM

2. Haemophagocytic Lymphohistiocytosis (HLH)

• - Gamifant® (emapalumab): Presenting data regarding transplant-related outcomes for HLH patients treated with this monoclonal antibody that neutralizes interferon gamma.

3. Myelofibrosis

• - Vonjo® (pacritinib): This treatment focuses on hematologic improvement seen in patients treated in real-world settings. Poster presentations will outline improvements in metabolic profiles post-treatment.

4. Paroxysmal Nocturnal Hemoglobinuria (PNH)

• - Aspaveli®/Empaveli® (pegcetacoplan): Insights into clinical outcomes for patients receiving treatment, showcasing the advancements in managing this rare disease.

5. Immune Thrombocytopenia (ITP)

• - Doptelet® (avatrombopag): Focused presentations will highlight the effectiveness of this medication in treating patients with chronic ITP, including analyses of patient experience and treatment satisfaction.

Sobi's Commitment to Rare Diseases

Sobi has a pivotal role in advancing treatments for rare hematological disorders, relying on innovative therapies and collaboration with partners like Sanofi and Apellis. Sobi has carved a niche in delivering tailored solutions for patients with severe and debilitating conditions through rigorous research and dedicated development.

With over 1,800 employees globally and a commitment to innovative medicines, Sobi is positioned to make a substantial difference in the lives of those affected by rare diseases. The insights shared at ASH 2024 will bolster our understanding and treatment approaches in these critical areas, ultimately aiming to enhance patient outcomes and quality of life.

For those interested in the latest advancements in haematology and collaborative efforts to improve patient care, visiting Sobi's presentations at ASH 2024 will be essential. The company is passionate about its mission to lead the way in addressing the unmet needs of patients across the globe.

Stay tuned for more updates as Sobi shares its transformative insights at the ASH conference!